Efficacy and Safety of Rituximab Therapy to Sustain Remission in Young Children With Childhood Nephrotic Syndrome

Kidney International Reports 2026 Open access

Read full text
Authors: Eugene Yu-hin Chan, Chun Ting Au, Ellen L.M. Yu, Andrea Angeletti, Zainab Arslan, Olivia Boyer, Chang‐Yien Chan, Manuela Colucci, Guillaume Dorval, Claire Dossier, Gian Marco Ghiggeri, Riku Hamada
+18 more Julien Hogan, Kenji Ishikura, Koichi Kamei, Markus J. Kemper, Alison Lap-tak Ma, Rulan S. Parekh, Seetha Radhakrishnan, Cal Robinson, Qian Shen, Rajiv Sinha, Chantida Subun, Sharon Teo, Marina Vivarelli, Hazel Webb, Hong Xu, Tomohiko Yamamura, Hui Kim Yap, Kjell Tullus
DOI: 10.1016/j.ekir.2026.106526
Cited by: 3
References: 39

Abstract

Background Efficacy and safety of rituximab in children under 6 years with frequently-relapsing and/or steroid-dependent nephrotic syndrome (FRSDNS) remain controversial. Methods We conducted a retrospective cohort study at 16 paediatric nephrology centres from 10 countries in Asia, Europe and North America. We first analysed young children with FRSDNS who received first rituximab before 6 years. As a secondary analysis, we matched young children

Fields of Study & Subjects

Renal Diseases and Glomerulopathies Vasculitis and related conditions Renal Transplantation Outcomes and Treatments

Publication details

Journal / source
Kidney International Reports
Publisher
Elsevier BV
Volume
11
Issue
6
Pages
106526–106526
Publication date
6 April 2026
Language
EN